U.S. Markets closed
  • S&P 500

    4,136.48
    -43.28 (-1.04%)
     
  • Dow 30

    33,926.01
    -127.93 (-0.38%)
     
  • Nasdaq

    12,006.96
    -193.86 (-1.59%)
     
  • Russell 2000

    1,985.53
    -15.69 (-0.78%)
     
  • Crude Oil

    73.23
    -2.65 (-3.49%)
     
  • Gold

    1,877.70
    -53.10 (-2.75%)
     
  • Silver

    22.40
    -1.22 (-5.17%)
     
  • EUR/USD

    1.0798
    -0.0113 (-1.0366%)
     
  • 10-Yr Bond

    3.5320
    +0.1360 (+4.00%)
     
  • Vix

    18.33
    -0.40 (-2.14%)
     
  • GBP/USD

    1.2056
    -0.0173 (-1.4106%)
     
  • USD/JPY

    131.1500
    +2.5460 (+1.9797%)
     
  • BTC-USD

    23,341.09
    -54.61 (-0.23%)
     
  • CMC Crypto 200

    535.42
    -1.43 (-0.27%)
     
  • FTSE 100

    7,901.80
    +81.64 (+1.04%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

Should You Invest in argenx SE (ARGX)?

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” third quarter 2022 investor letter. A copy of the same can be downloaded here. In the third quarter, its Investor Class fund ARTSX returned 3.23%, Advisor Class fund APDSX posted a return of 3.27%, and Institutional Class fund APHSX returned 3.27%, compared to a return of 0.24% for the Russell 2000 Growth Index. In addition, please check the fund’s top five holdings to know its best picks in 2022.

In the third-quarter letter, Artisan Partners discussed stocks like argenx SE (NASDAQ:ARGX). Headquartered in Breda, the Netherlands, argenx SE (NASDAQ:ARGX) is a biotechnology company. On November 11, 2022, argenx SE (NASDAQ:ARGX) stock closed at $363.07 per share. One-month return of argenx SE (NASDAQ:ARGX) was 0.56% and its shares gained 20.54% of their value over the last 52 weeks. argenx SE (NASDAQ:ARGX) has a market capitalization of $20.409 billion.

Artisan Partners made the following comment about argenx SE (NASDAQ:ARGX) in its Q3 2022 investor letter:

"Among our bottom contributors were Argenx, Halozyme and Azenta. argenx SE (NASDAQ:ARGX) has given back some of its YTD gains despite sales for VYVGART—used to treat a chronic neuromuscular condition (myasthenia gravis)—pacing well ahead of expectations for the second straight quarter (2X higher than Street estimates). VYVGART’s outperformance has been demand-driven, with ~1,400 patients now on the drug (versus 380 in Q1). We believe the second indication for VYVGART will receive FDA approval in early 2023, and there is potential for the drug to treat numerous other rare autoimmune disorders longer term."

Pressmaster/Shutterstock.com

argenx SE (NASDAQ:ARGX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held argenx SE (NASDAQ:ARGX) at the end of the second quarter which was 31 in the previous quarter.

We discussed argenx SE (NASDAQ:ARGX) in another article and shared Baron Funds’ views on the company. In addition, please check out our hedge fund investor letters Q3 2022 page for more investor letters from hedge funds and other leading investors.

 

Suggested Articles:

Disclosure: None. This article is originally published at Insider Monkey.